ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its financial and operational results for Q4 and the full-year 2025, highlighting upcoming clinical milestones for its lead product, ZYNLONTA. The company recorded Q4 net product revenue of $22.3 million and full-year revenue of $73.6 million, driven by stable demand and higher selling prices. With $261.3 million in cash and cash equivalents as of December 31, 2025, the company expects its current cash runway to extend at least into 2028.

The company is approaching several value-creating catalysts in its clinical pipeline, specifically targeting diffuse large B-cell lymphoma/DLBCL. Topline data from the LOTIS-5 Phase 3 confirmatory trial is expected in Q2 2026, with full results for both LOTIS-5 and the LOTIS-7 Phase 1b trial anticipated by year-end. If these results are positive, the company plans to pursue sBLA and potential compendia inclusions in 2027. Additionally, investigator-initiated trials are evaluating ZYNLONTA for other B-cell malignancies, including follicular lymphoma and marginal zone lymphoma, with data expected between late 2026 and mid-2027.

ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028

Pressmaster/Shutterstock.com

Financial performance for 2025 showed a significant reduction in net loss, which totaled $142.6 million for the full year compared to $157.8 million in 2024. This improvement was attributed to lower R&D expenses following the discontinuation of certain programs and a reprioritization initiated in June 2025. Total adjusted operating expenses also decreased year-over-year as ADC Therapeutics (NYSE:ADCT) optimized its organizational structure.

ADC Therapeutics (NYSE:ADCT) is a healthcare company that offers an antibody drug conjugate/ADC technology platform with flagship products that include ZYNLONTA, which is a CD19-directed ADC.

While we acknowledge the risk and potential of ADCT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADCT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.